The Diagnostic Performance of PSMA PET/CT In Patients With Biochemically Recurrent Prostate Cancer After Radical Treatment

Συγγραφείς

  • Ahmed Tawakol MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
  • Sherif El-Refaei MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
  • Mohamed Houseni MD, Department of Radiology, National Liver Institute, Egypt
  • Eman Ashraf Mousa MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
  • Mohamed Abdel latif Shahin MD, Department of Radiodiagnosis Faculty of Medicine, Cairo University, Egypt

Λέξεις-κλειδιά:

PSMA PET/CT, biochemically recurrent prostate cancer

Περίληψη

Purpose of the study: To assess the role of PSMA ligands Positron Emission Tomography and Computed Tomography (PET/CT) Scans in the biochemical recurrence of prostate cancer post radical treatment.

Materials and methods: Our prospective study included 131 males with proven biochemical recurrent prostatic adenocarcinoma. The patients’ images and data were analyzed for the rate of detection of recurrence based on PROMISE criteria. Also, correlation between the level of serum PSA and detection rate of PSMA PET/CT was analyzed. Moreover, estimation of a cutoff value for the level of serum PSA to distinguish between positive and negative PSMA PET/CT was performed.

Results: The overall detection rate was 102/131 patients (77.8 %). There was positive relation between serum PSA before the scan and the positivity of PSMA PET/CT. The most common sites of recurrence were operative bed/ radiated prostate, pelvic lymph nodes, osseous deposits, retro-peritoneal lymph nodes and visceral deposits. The cutoff value for serum PSA level to differentiate between positive PSMA PET/CT scan from a negative one to be>0.73 ng/ml.

Conclusion: PSMA PET/CT has a pivotal role in cases with biochemical recurrence after radical treatment of prostate cancer.

Βιογραφικά Συγγραφέων

  • Ahmed Tawakol , MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
    Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university.  
  • Sherif El-Refaei, MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
    MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university.  
  • Mohamed Houseni , MD, Department of Radiology, National Liver Institute, Egypt
    MD, Department of Radiology, National Liver Institute  
  • Eman Ashraf Mousa , MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university, Egypt
    MD, Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Cairo university.  
  • Mohamed Abdel latif Shahin , MD, Department of Radiodiagnosis Faculty of Medicine, Cairo University, Egypt
    MD, department of radiodiagnosis Faculty of medicine, Cairo university, Egypt  

Λήψεις

Δημοσιευμένα

2025-11-03

Τεύχος

Τόμ. 9 Αρ. 2 (2024)

Ενότητα

Original Articles